Page last updated: 2024-11-11

palitantin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

palitantin: RN given refers to (2alpha,3beta(1E,3E),5alpha,6alpha)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6438427
CHEMBL ID367001
SCHEMBL ID3119540
MeSH IDM0282530

Synonyms (32)

Synonym
palitantin
nsc-246119
CHEMBL367001 ,
(2r,3s,5r,6r)-3-((1e,3e)-hepta-1,3-dienyl)-5,6-dihydroxy-2-hydroxymethyl-cyclohexanone
bdbm50056875
(2r,3r,5s,6r)-5-[(1e,3e)-hepta-1,3-dienyl]-2,3-dihydroxy-6-(hydroxymethyl)cyclohexan-1-one
15265-28-8
cyclohexanone, 3-(1,3-heptadienyl)-5,6-dihydroxy-2-(hydroxymethyl)-, (2alpha,3beta(1e,3e),5alpha,6alpha)-
unii-25m588oezf
25m588oezf ,
nsc 246119
cyclohexanone, 3-(1e,3e)-1,3-heptadien-1-yl-5,6-dihydroxy-2-(hydroxymethyl)-, (2r,3s,5r,6r)-
140224-89-1
05d54kln3m ,
unii-05d54kln3m
palitantin, (+)-
(+)-palitantin
(+/-)-palitantin
rel-(2r,3s,5r,6r)-3-(1e,3e)-1,3-heptadien-1-yl-5,6-dihydroxy-2-(hydroxymethyl)cyclohexanone
cyclohexanone, 3-(1e,3e)-1,3-heptadienyl-5,6-dihydroxy-2-(hydroxymethyl)-, (2r,3s,5r,6r)-rel-
palitantin [mi]
SCHEMBL3119540
(2r,3s,5r,6r)-3-(1e,3e)-1,3-heptadien-1-yl-5,6-dihydroxy-2-(hydroxymethyl)cyclohexanone
cyclohexanone, 3-(1e,3e)-1,3-heptadienyl-5,6-dihydroxy-2-(hydroxymethyl)-, (2r,3s,5r,6r)-
cyclohexanone, 3-(1,3-heptadienyl)-5,6-dihydroxy-2-(hydroxymethyl)-, (2r-(2.alpha.,3.beta.(1e,3e),5.alpha.,6.alpha.))-
HB4012
DTXSID60161262
J-008944
DTXSID601017488
(2r,3s,5r,6r)-3-[(1e,3e)-hepta-1,3-dien-1-yl]-5,6-dihydroxy-2-(hydroxymethyl)cyclohexan-1-one
HY-120154
CS-0077035
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Integrase Human immunodeficiency virus 1IC50 (µMol)260.50000.00051.544310.0000AID93690; AID93691; AID93696; AID93697
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID93688Inhibitory concentration against purified recombinant integrase by 3'-processing in 3D search (experiment 2)1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Discovery of HIV-1 integrase inhibitors by pharmacophore searching.
AID91577Percentage inhibition was obtained by performing in vitro assay on purified recombinant integrase by strand transfer method at 100 micro g/mL1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Discovery of HIV-1 integrase inhibitors by pharmacophore searching.
AID93691Inhibitory concentration against purified recombinant integrase by 3'-processing in vitro assay (experiment 2)1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Discovery of HIV-1 integrase inhibitors by pharmacophore searching.
AID93693Inhibitory concentration against purified recombinant integrase by strand transfer 3D search (experiment 1)1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Discovery of HIV-1 integrase inhibitors by pharmacophore searching.
AID93694Inhibitory concentration against purified recombinant integrase by strand transfer 3D search (experiment 2)1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Discovery of HIV-1 integrase inhibitors by pharmacophore searching.
AID93697Inhibitory concentration against purified recombinant integrase by strand transfer in vitro assay (experiment 2)1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Discovery of HIV-1 integrase inhibitors by pharmacophore searching.
AID93687Inhibitory concentration against purified recombinant integrase by 3'-processing in 3D search (experiment 1)1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Discovery of HIV-1 integrase inhibitors by pharmacophore searching.
AID93690Inhibitory concentration against purified recombinant integrase by 3'-processing in vitro assay (experiment 1)1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Discovery of HIV-1 integrase inhibitors by pharmacophore searching.
AID91563Percentage inhibition was obtained by performing in vitro assay on purified recombinant integrase by 3''-processing method at 100 micro g/mL1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Discovery of HIV-1 integrase inhibitors by pharmacophore searching.
AID93696Inhibitory concentration against purified recombinant integrase by strand transfer in vitro assay (experiment 1)1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Discovery of HIV-1 integrase inhibitors by pharmacophore searching.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (33.33)18.7374
1990's2 (22.22)18.2507
2000's2 (22.22)29.6817
2010's1 (11.11)24.3611
2020's1 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.35 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.65 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.35)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]